Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

Gennaro Riccio, Carmela Coppola, Giovanna Piscopo, Immacolata Capasso, Carlo Maurea, Emanuela Esposito, Claudia De Lorenzo, Nicola Maurea

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?'. Together they form a unique fingerprint.

Medicine & Life Sciences